June, 2025
June 2025
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Overall survival by ctDNA status and clecoxib use in Colorectal Cancer
Jan 30, 2025, 04:03

Overall survival by ctDNA status and clecoxib use in Colorectal Cancer

Keith Hanigan, Vice President Oncology Marketing at Natera, shared a post on LinkedIn:

“So many highlights from Natera at ASCO GI this weekend, including a successful readout of the 80702 trial in colorectal cancer.

Of note, Signatera-positive patients treated with both adjuvant chemotherapy and celecoxib showed a 40% improvement in overall survival versus chemotherapy alone. This marks an unprecedented moment in personalized medicine for patients with colorectal cancer.

Thank you to all involved in this first-of-its-kind study.”

 Overall survival by ctDNA status and clecoxib use in Colorectal Cancer